Cuprina Holdings (Cayman) LTD
No enriched coverage for $CUPR in the last 7 days.
No SEC Form 4 filings for $CUPR in the last 30 days.
See all $CUPR insider activity →Cuprina (Nasdaq: CUPR) to acquire East Coast Podiatry and Orchard Clinic for S$4.0M (US$3.1M). Target generated FY2025 revenue of S$9.1M (US$7.0M) and EBITDA of S$1.2M (US$0.9M). Deal aligns with Cuprina's wound-care and collagen tech.
Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) closed the sale of 648,373 additional shares at $1.15 per share, raising $745,629. Total gross proceeds from the offering are $5,716,491. The company plans to use funds for expansion, R&D, and working capital. R. F. Lafferty & Co. acted as the sole book-running manager.
Cuprina Holdings (CUPR), a Singapore-based wound care company, priced its Nasdaq IPO at $1.15 per share, raising $5 million. R.F. Lafferty is the sole underwriter, which may limit liquidity and impact early trading.
Recent CUPR coverage spans market movers, financial news and regulation.
The acquisition expands Cuprina's clinical footprint and could boost future earnings, but the cash outlay and share issuance may dilute existing shareholders in the short term.
The additional capital modestly strengthens the balance sheet and may support R&D and expansion plans.
First‑day pricing creates immediate trading opportunity; thin liquidity may cause volatile price swings.
Near-term catalyst is the start of maiden drilling and ongoing geophysics, supported by stated funding; near-term trading likely follows drill-readiness and financing credibility.
FDA 510(k) clearance is a concrete regulatory milestone that can improve commercialization prospects and near-term sentiment.
AlphAI scores every news story that mentions CUPR with an AI model for sentiment and relevance, and aggregates insider trades from Cuprina Holdings (Cayman) LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cuprina (Nasdaq: CUPR) to acquire East Coast Podiatry and Orchard Clinic for S$4.0M (US$3.1M). Target generated FY2025 revenue of S$9.1M (US$7.0M) and EBITDA of S$1.2M (US$0.9M). Deal aligns with Cuprina's wound-care and collagen tech.
2 min readCuprina Holdings (Cayman) Limited (Nasdaq: CUPR) closed the sale of 648,373 additional shares at $1.15 per share, raising $745,629. Total gross proceeds from the offering are $5,716,491. The company plans to use funds for expansion, R&D, and working capital. R. F. Lafferty & Co. acted as the sole book-running manager.
1 min readCuprina Holdings (CUPR), a Singapore-based wound care company, priced its Nasdaq IPO at $1.15 per share, raising $5 million. R.F. Lafferty is the sole underwriter, which may limit liquidity and impact early trading.
1 min readSuper Copper Corp. (CSE: CUPR, OTCQB: CUPPF) said it is mobilizing for a maiden diamond drill program at the El Alto target in Chile, planning up to 15 holes and about 5,000 m to test an 800 m-plus chargeability corridor. It reported Phase 1 geophysics completed at Castilla and said it is fully funded after a March 2026 financing. It also outlined a 15-month biopolymer R&D program for copper processing and remediation.
7 min readThe article highlights premarket moves in several stocks, including Cuprina Holdings, CEA Industries, Absci and Wendy’s, as of 7:10 a.m. ET. It also notes Cuprina said it received U.S. FDA 510(k) clearance for its MEDIFLY maggot debridement product, according to a company release.
2 min readBiotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min readThe FDA cleared Cuprina Holdings’ second fly species for maggot wound therapy, the company said. Along with Lucilia sericata (cleared since 2004), Cuprina received clearance for Lucilia cuprina (Australian sheep blowfly). Cuprina said it is the only company with FDA clearance for two larvae species; it made no claim of major therapeutic differences.
6 min readRegentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
6 min readCuprina Holdings (Cayman) Limited (CUPR) shares rose about 114% on Friday after the company regained compliance with Nasdaq Capital Markets listing requirements, according to the report. The stock traded around $5.16, up 114.12%, after opening at $3.26 and reaching an intraday high of $8.23.
2 min readCuprina Holdings (Cayman) (NASDAQ:CUPR) shares rose 49.3% on Thursday, trading between $3.70 and $3.30 after closing at $2.21. Volume was 3.16M shares, up 2,429% vs. average. Weiss Ratings reaffirmed a “sell (e+)” rating. The company reported Q1 EPS of -$0.40 on revenue of $0.01M.
4 min read
